Cardiovascular Research

Cardiovascular Research 2001 50(3):556-565; doi:10.1016/S0008-6363(01)00220-6
© 2001 by European Society of Cardiology

This Article Abstract FREE Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Disclaimer Google Scholar Articles by Bond, M. Articles by Newby, A. C Search for Related Content PubMed PubMed Citation Articles by Bond, M. Articles by Newby, A. C Social Bookmarking          What's this?

Copyright © 2001, European Society of Cardiology

Inhibition of transcription factor NF-B reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells

Mark Bond^a,*, Alex J Chase^a, Andrew H Baker^b and Andrew C Newby^a

^aBristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW, UK
^bDepartment of Medicine and Therapeutics, University of Glasgow, Glasgow, G11 6NT, UK

^* Corresponding author. Tel.: +44-1179-283-582; fax: +44-1179-283-581 mark.bond{at}bristol.ac.uk a.newby{at}bristol.ac.uk

Received 29 November 2000; accepted 15 January 2001

	Abstract

Top Abstract 1 Introduction 2 Experimental procedures 3 Results 4 Discussion References

 
Objective: Matrix metalloproteinases (MMPs) contribute to the destruction of the extracellular matrix at the shoulder regions of atherosclerotic plaques that leads to plaque destabilisation and triggers clinical cardiovascular disease. There is therefore considerable interest in establishing the mechanisms responsible for increased MMP production. MMPs-1, -3 and -9 are upregulated by inflammatory cytokines and growth factors that are produced by plaque resident macrophages and smooth muscle cells. Our present studies focused on NF-B, which regulates numerous inflammatory genes, and is activated in plaque smooth muscle cells. Moreover, an NF-B binding site is present in the promoter of the MMP-9 gene and an NF-B-like element in the promoter of the MMP-1 gene. Methods: We used adenovirus mediated overexpression of its inhibitor, IB to investigate the role of NF-B in regulation of MMP-1, -3 and -9 by isolated, cytokine stimulated rabbit aortic and human saphenous vein VSMC. Results: IL-1 potently activated NF-B in VSMCs and acted synergistically with growth factors to upregulate expression of MMP-1, -3 and -9. Overexpression of IB, almost completely inhibited expression of MMP-1, -3 and -9 in response to IL-1 alone or in combination with bFGF and PDGF. Conclusion: NF-B is required for cytokine upregulation of MMP-1, -3 and -9 in VSMCs, which suggests that NF-B inhibition may promote plaque stabilisation.

KEYWORDS bFGF, basic fibroblast growth factor; EMSA, electromobility shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-1, interleukin-1; MMP, matrix metalloproteinase; PDGF, platelet derived growth factor; TNF-, tumour necrosis factor-

	1 Introduction

Top Abstract 1 Introduction 2 Experimental procedures 3 Results 4 Discussion References

 
The acute coronary syndromes of unstable angina and myocardial infarction most often result from thrombus formation at a site of atherosclerotic plaque rupture. A pathological feature characteristic of the unstable plaque is attenuation of the collagenous extra-cellular matrix, producing areas of structural weakness within the fibrous cap, the barrier between the highly thrombogenic lipid core and the circulating blood [1,2]. Collagen destruction is attributed to increased production of several matrix metalloproteinases (MMPs) by vascular smooth muscle cells (VSMCs) and inflammatory cells, which together can catalyse the complete destruction of interstitial collagen. Both human work and animal models have demonstrated MMP activity within atherosclerotic plaques [3–7]. In vitro studies have demonstrated regulation of MMP-1, -3 and -9 genes by growth factors and inflammatory cytokines produced by plaque resident cells [8,9]. In rabbit VSMCs we demonstrated that MMP-9 secretion is potently and synergistically induced by a combination of the inflammatory cytokine interleukin-1 (IL-1) and the connective tissue mitogen platelet derived growth factor_BB (PDGF_BB) mimicking the in vivo environment of the atherosclerotic plaque where sources of both are present [9]. The transcription factor nuclear factor kappa-B (NF-B) is involved in the regulation of several inflammation related genes and active NF-B has been demonstrated within the atherosclerotic lesion [10–12]. Inflammatory stimuli known to stimulate MMP production from vascular smooth muscle cells including IL-1 and CD40-CD-40 ligand interactions are known to activate NF-B [10,11]. Furthermore, other processes implicated in atherogenesis such as oxidative stress and vascular injury also result in NF-B activation. The role of NF-B in the regulation of MMP-1, -3 and -9 however remains unclear. The presence of an NF-B binding site in the MMP-9 promoter [13,14] and a recently identified NF-B-like element in the MMP-1 promoter [15] prompted us to investigate the role of NF-B in the regulation of MMP-1 and -9 in both rabbit and human vascular smooth muscle cells. Using adenovirus mediated gene delivery of IB [16] the physiological inhibitor of NF-B, we demonstrate that NF-B plays an essential role in MMP-1 and -9 upregulation. Surprisingly, upregulation of MMP-3 production was profoundly inhibited despite lack of analogous NF-B sites within the MMP-3 promoter region. The results obtained are important because they reveal potential for NF-B inhibition as a therapy to promote plaque stabilisation.

	2 Experimental procedures

Top Abstract 1 Introduction 2 Experimental procedures 3 Results 4 Discussion References

 
2.1 Materials
Human recombinant PDGF_BB was purchased from Boehringer Mannheim Ltd, Lewes, East Sussex, UK. Basic FGF (bFGF) was purchased from Promega, Southampton, UK. Human recombinant IL-1- was a generous gift from Roche Products, Welwyn Garden City, Herts., UK. Sheep antisera to rabbit MMP-1 and rabbit MMP-3 were generously given by Dr G. Murphy, School of Biological Sciences, University of East Anglia, Norwich, UK. Rabbit antisera to human MMP-1 and human MMP-3 were gifts from Pfizer, Sandwich, UK. Rabbit polyclonal antibody to IB purchased from Santa Cruz (Delaware Avenue, California). Plasmid pSP64 (human collagenase) was a gift from Dr Andrew Docherty, Celltech Ltd, Slough, UK. Recombinant adenovirus capable of overexpressing the porcine IB gene (rAd:IB) was a kind gift from Dr Rainer De Martin, Department of Vascular Biology and Thrombosis Research, University of Vienna, Austria [16]. Recombinant adenoviruses capable of overexpressing the bacterial LacZ gene (rAd:βGal) and a control virus with a silent expression cassette (rAd:null) were kind gifts from Dr G. Wilkinson, Department of Cardiology and Medicine, University of Wales College of Medicine, Heath Park, Cardiff, UK [17]. This investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996).

2.2 Methods
2.2.1 Cell culture
Primary cultures of human saphenous vein and rabbit aortic smooth muscle cells were prepared by modifications of the explant technique, as previously described in detail [18]. Explants were maintained in complete medium composed of DMEM containing penicillin–streptomycin (100 Units/ml and 100 µg/ml, respectively), 1 mM sodium pyruvate, 8 mM L-glutamine and 15% foetal bovine serum (FBS, Advanced Protein Products, UK). After 10–14 days, cells were subcultured by trypsin/EDTA treatment. Cells between passage one to three were plated at a density of 7x10⁴ cells/well into 12-well culture plates for zymography and western blotting or 8x10⁵ cells/75 cm² flasks for RNA studies. For all experiments, sub-confluent cells were rendered quiescent by incubation in serum-free DMEM supplemented with 0.25% (v/v) lactalbumin hydrolysate (Gibco BRL, Paisley, UK) for 3 days. Cultures were then exposed to fresh serum-free medium containing the appropriate concentration of the agent under investigation for varying time intervals.

2.2.2 Zymography
Gelatinase activity was detected in conditioned media as previously described [18]. Briefly, 10 µl aliquots of non-reduced conditioned media were electrophoresed at 4°C in 7.5% SDS–polyacrylamide gels containing 2 mg/ml gelatin derived from calf skin collagen (Sigma, type III). After removal of SDS gelatinase activity was revealed by overnight incubation at 37°C and staining with 0.1% Coomassie Brilliant Blue. Zymograms were quantified in the linear range by densitometry as described previously [19] using a Biorad GS 690 Image Analysis software system (Biorad Laboratories, Hemel Hempstead, Hertfordshire, UK) and were related to a standard mixture of MMP-2 and -9 run on each zymogram.

2.2.3 Western blotting
Western blots were performed on conditioned media samples concentrated 10-fold by ultrafiltration using Amicon 10 centrifugal concentrators (Amicon, Stonehouse, Gloucestershire, UK). Samples were subjected to SDS–polyacrylamide gel electrophoresis under reducing conditions and proteins were then electrophoretically transferred to Hybond-nitrocellulose membrane (Amersham International, Little Chalfont, Buckinghamshire, UK). Membranes were blocked in TBS–Tween (200 mM Tris/HCl, pH 7.4, 137 mM NaCl, 0.1% Tween 20) containing 5% skimmed milk powder followed by incubation with primary antibody. Following washing in TBS–Tween, blots were incubated with a horseradish peroxidase conjugated secondary antibody for 60 min and immunoreactive proteins visualised using the Enhanced Chemiluminescence (ECL) system (Amersham International). Bands were quantified by densitometry as described above.

2.2.4 Preparation of RNA probes
Antisense riboprobes for MMP-9 and GAPDH have been described previously [20]. MMP-1 riboprobe template was generated by PCR from a plasmid containing a partial MMP-1 cDNA (pSP64 human collagenase) using primers designed using published sequence data [21]. MMP-3 riboprobe template was generated by RT-PCR from IL-1 stimulated rabbit smooth muscle cell total RNA. For human MMP-1, primer sequences were sense (5'-GGT GAT GAA GCA GCC CAG-3') and antisense (5'-CAG TAG AAT GGG AGA GTC-3') and for rabbit MMP-3 sense (5'-GC ATC AAG ACA GCA TAG AGC TGA GTA AAG C-3') and antisense (5'-GAC AGG TTC CAT AGG CAC TTC AGA GTT ATC-3'). PCR products were cloned into PCR II vector (Invitrogen BV, NV Leek, Netherlands) that contains flanking SP6 and T7 promoters and their identity confirmed by diagnostic restriction fragment mapping and hybridization to mRNA transcripts of expected size. Antisense digoxygenin labelled riboprobes were generated from linearized plasmid using the DIG RNA labelling kit according to the manufacturers instructions (Boehringer Mannheim).

2.2.5 Northern analysis
Total cellular RNA was prepared from 1x10⁶ rabbit aortic SMC using Qiagen Rneasy total RNA extraction columns (Hybaid Ltd., Teddington, Middlesex, UK) according to the maunufacturer's instructions, and quantified by absorbance at 260 nm. First, 10 µg of RNA was fractionated on 1% agarose/2.2 M formaldehyde gels and transferred on to Hybond-N membranes (Amersham International) by capillary blotting overnight using 20x SSC (3 M sodium chloride, 300 mM sodium citrate). RNA was cross-linked to the membrane by UV irradiation (150 000 µJ/cm²) and stained with 0.03% methylene blue in 0.3 M sodium acetate, pH 5.2 to assess RNA integrity and equality of loading and transfer.

Prehybridization of the blots was carried out at 64–68°C in a buffer containing 50% (v/v) formamide, 5x SSC, 0.1% sodium lauroylsarcosine, 0.02% SDS, 1% blocking reagent (Boehringer Mannheim) for 1 h. Blots were subsequently hybridized in the same buffer overnight with 100 ng/ml DIG-labelled RNA probes. Post-hybridization was carried out at room temperature using 2x SSC, 0.1% SDS for 10 min followed by higher stringency washes with 0.2x SSC, 0.1% SDS at 64–68°C. Specifically hybridized probe was detected using the DIG-detection system (Boehringer Mannheim). Bands were quantified using a Biorad GS 690 Image Analysis software system.

2.2.6 Nuclear extracts and electrophoretic mobility shift assay
Nuclear proteins were extracted from approximately 1x10⁶ rabbit smooth muscle cell nuclei as previously described [22]. Binding reactions (20 µl) containing 2 µg Poly(dI-dC), 10 mM HEPES, pH 7.9; 50 mM NaCl, 0.5 DDT, 2.5 mM EDTA, 7 mM MgCl₂, 4% glycerol, and 4–6 µg nuclear extract were incubated on ice for 30 min with 20 000 cpm of ³²P-labelled oligonucleotide corresponding to the rabbit MMP-9 NF-B element (5'-CCC CGG TGG AAT TCC CCA AAT CCT-3') or the proximal AP-1 element (5'-CCG GCC CTG AGT CAG CAC TTG CCT G-3'). Complexes were separated on 6% nondenaturing polyacrylamide gels and visualised by autoradiography.

2.2.7 Adenovirus-driven overexpression of IB
A recombinant adenovirus carrying the porcine IB gene (rAd:IB) [16] was used to overexpress IB protein in cultures of rabbit and human vascular smooth muscle cells. The adenovirus titre required to produce a 100% infection efficiency (600 pfu/cell for rabbit VSMCs and 1000 pfu/cell for human VSMC) was determined histochemically using an adenovirus capable of expressing the bacterial LacZ gene. Rabbit and human smooth muscle cells were infected with 600 and 1000 pfu/cell of rAd:IB, respectively, for 16 h in serum free medium. IB transgene expression was analysed 3 days post-infection by western blotting as detailed above.

	3 Results

Top Abstract 1 Introduction 2 Experimental procedures 3 Results 4 Discussion References

 
3.1 Combinations of growth factors and cytokines synergistically stimulate MMP-9 expression in rabbit aortic and human saphenous vein smooth muscle cells
In agreement with our previous data [9] combinations of PDGF_BB and IL-1 synergistically enhanced secretion of MMP-9 from rabbit VSMC (Fig. 1A). Even greater effects were seen with combinations of bFGF and IL-1 (Fig. 1A). Similar results were found when TNF- was substituted for IL-1 (results not shown).

View larger version (49K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 1 Synergistic regulation of MMP-1, -3 and -9 secretion by combinations of IL-1 with PDGFBB or bFGF. Quiescent cultures of rabbit and human VSMC were stimulated with either 10 ng/ml IL-1, 20 ng/ml bFGF, 20 ng/ml PDGFBB or combination of IL-1 with either PDGFBB or bFGF as indicated. Cell conditioned medium was collected after 18 h for rabbit cells and 48 h for human cells due to lower levels of secretion by HVSMC. VSMC analysed for (A) MMP-2 and MMP-9 secretion by gelatin zymography and (B) MMP-1 and MMP-3 secretion by Western blotting. The results are representative of three similar experiments.

 
A similar synergistic pattern of regulation was found in human saphenous vein smooth muscle cells despite lower maximal level of secretion (Fig. 1A). In the human cells, bFGF was only as effective as PDGF_BB (Fig. 1A), which may reflect differences in receptor levels between these cell types. No changes in MMP-2 levels were seen in either cell type (Fig. 1A).

3.2 Effect of combinations of growth factors and IL-1 on secretion of MMP-1 and MMP-3
In rabbit VSMC, secretion of MMP-1 and MMP-3 (Fig. 1B) was low in the presence of bFGF alone but was increased synergistically by combinations of bFGF with IL-1. Responses to bFGF and IL-1 were comparable with those to phorbol myristate acetate (PMA, data not shown). In human cells MMP-1 secretion was submaximally upregulated by IL-1 or PDGF alone (Fig. 1B). Combinations of these agonists acted additively to increase MMP-1 secretion. MMP-3 secretion mirrored that observed in rabbit cells, being synergistically upregulated by a combination of PDGF_BB and IL-1 (Fig. 1B)

Using rabbit cells we investigated whether increased MMP secretion was mediated by increases in MMP mRNA levels. As shown in Fig. 2, mRNA levels of MMPs-1, -3 and -9 were all strongly and synergistically upregulated by combinations of bFGF with IL-1. Levels of GAPDH mRNA, used as a housekeeping gene, did not alter under any conditions of stimulation (Fig. 2).

View larger version (56K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 2 Synergistic regulation of MMP-1, MMP-3 and MMP-9 mRNA by a combination of IL-1 with bFGF. Quiescent rabbit VSMC were stimulated for 4 h with 10 ng/ml IL-1, 20 ng/ml bFGF, 10 ng/ml IL-1 plus 20 ng/ml bFGF or 10–7 M phorbol ester. Total RNA was extracted and analysed for MMP-1, -3 and -9 mRNA by Northern blotting. The house-keeping gene GAPDH was used as a control for RNA integrity and equal loading.

 
3.3 Activation of NF-B and its inhibition by overexpression of IB
NF-B activity, measured by electrophoretic mobility shift assay, was increased after 3 h stimulation by IL-1, but not bFGF, with no synergy between them (Fig. 3A). EMSA were analysed by densitometric analysis and expressed as a percentage of the binding induced by bFGF+IL-1 (control: 12.6±10.4%; IL-1: 105.4±18.7%; bFGF: 13.2±6.2%). Sub-maximal levels of NF-B DNA binding were detected after prolonged (18 h) stimulation with bFGF (data not shown). The specificity of the binding was demonstrated by competition with specific ODNs and with supershift with antibodies to the p65/RelA subunit (Fig. 3C). Nuclear translocation of NF-B measured by immunofluoresence demonstrated the same pattern of regulation by IL-1 but not bFGF (results not shown).

View larger version (57K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 3 EMSA analysis of NF-B activation and its inhibition by IB. (A) Quiescent rabbit VSMC were stimulated for 3 h with 10 ng/ml IL-1, 20 ng/ml bFGF or a combination of IL-1 plus bFGF. Nuclear extracts were prepared and analysed for NF-B and AP-1 DNA binding by EMSA. Binding specificity was demonstrated by competition with 100-fold excess of unlabelled specific or non-specific oligonucleotide. (B) Rabbit VSMC were infected with rAd:null of rAd:IB and rendered quiescent by 72 h serum deprivation. Cells were then stimulated for 3 h with 10 ng/ml IL-1 plus 20 ng/ml bFGF. Nuclear extracts were prepared and analysed for NF-B and AP-1 DNA binding. (C) Identity of the binding complex was confirmed by supershift with anti-p65/NF-B antibody.

 
To establish whether activation of NF-B was essential for upregulation of MMP-9 we used adenovirus mediated overexpression of nuclear localised IB, the inhibitory subunit NF-B. Infection conditions were optimised using adenovirus carrying the bacterial LacZ β-galactosidase reporter gene. X-gal staining of infected cells demonstrated a multiplicity of infection of 600 and 1000 virus particles per cell yielded 100% infection in rabbit VSMC and HSV SMC, respectively (results not shown). Infection of rabbit VSMC with rAd:IB but not the control adenovirus rAd:null increased expression of IB detected 3 days later by Western blotting (Fig. 4A). Moreover, upon stimulation with IL-1, endogenous IB was degraded, as expected (Fig. 4B), but high levels of exogenous IB remained in the cells infected with rAd:IB, possibly due to the high levels of expression achieved and the nuclear localisation of this protein. Infection of HSV SMC with rAd:IB but not rAd:null caused a similar overexpression of IB as seen in rabbit cells (Fig. 4A). Infection with rAd:IB almost completely suppressed NF-B DNA binding (Fig. 3B). As a control for the DNA binding the specificity of IB overexpression we measured the effect of infection with rAd:IB on AP-1 DNA binding. AP-1 DNA binding activity was increased more than additively by a combination of IL-1 and bFGF (Fig. 3A). AP-1 binding was analysed by densitometric analysis and expressed as a percentage of the binding induced by bFGF+IL-1 (control: 10.3±4.2%; IL-1: 31±0.4%; bFGF: 27.3±5.6%). This binding was competed by specific ODNs (Fig. 3A). Unlike the results for NF-B binding, overexpression of IB did not affect AP-1 binding stimulated by IL-1 and bFGF (Fig. 3B).

View larger version (49K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 4 Adenovirus-mediated overexpression of IB. Rabbit and human VSMC were infected with rAd:IB or rAd:null and rendered quiescent by serum deprivation for 72 h. (A) Cell lysates were collected and analysed for IB expression by Western blotting. (B) Cells were stimulated with 10 ng/ml IL-1 for times indicated before cell lysates were collected and analysed for IB expression by Western blotting. Top panel: endogenous IB levels; lower panel: adenovirus mediated expression IB (ns indicates a non-specific band).

 
As further controls for the specificity of the effects of IB overexpression we measured its effect on cell viability and proliferation in rabbit VSMC under serum-free conditions similar to those used for the MMP secretion studies. Levels of cellular ATP (nmol/µg DNA, n=3), which were 0.48±0.03 in uninfected cells, were unaltered 3 days after infection with rAd:IB (0.55±0.04) or rAd:null (0.51±0.03), demonstrating that virus infection and IB overexpression had no adverse effect on cell viability. Cellular proliferation, measured as [³H]thymidine incorporation 24 h after addition of PDGF or bFGF (1000 dpm/µg DNA) was not significantly different in rAd:IB (38±8 for PDGF and 61±4 for bFGF) and rAd:null (56±5 for PDGF and 52±7 for bFGF) infected cells. Hence overexpression of IB had no effect on the various transcription factor events that led to proliferation. Taken together, these data all support the conclusion that overexpression of IB had a specific effect on NF-B activity.

3.4 Effect of overexpression of IB on MMP-1, -3 and -9 production rabbit and human vascular smooth muscle cells
Infection of rabbit VSMC with rAd:IB but not rAd:null completely suppressed upregulation of MMP-9 in response to IL-1 alone, and the much greater response to IL-1 in the presence of PDGF or bFGF. Upregulation of MMP-9 secretion in response to phorbol ester stimulation was also inhibited by overexpression of IB (Fig. 5A). Infection with rAd:null or rAd:IB did not affect the constitutive expression of MMP-2, demonstrating that the effect was selective and providing further evidence against and effect on cell viability. Infection with rAd:IB but not rAd:null also greatly suppressed the upregulation of MMPs-1 and -3 (Fig. 5B). To establish whether activation of NF-B was also essential in for upregulation of MMP-1, -3 and -9 by human VSMCs in response to stimulation with IL-1 and PDGF_BB we again employed adenovirus mediated overexpression of the inhibitory subunit IB. Infection of human VSMC with rAd:null significantly stimulated expression of MMP-1 and MMP-9 in response to IL-1 and PDGF (Fig. 6A,B) and had no effect on MMP-3 (Fig. 6A,B). Similar effects of adenovirus infection alone have been reported for other NF-B regulated genes and most likely reflects activation of NF-B by adenovirus infection [23–25]. Infection with rAd:IB but not rAd:null suppressed upregulation of MMP-9 by 77±12% (P<0.0001, n=8) but again had no effect on constitutive expression of MMP-2 (Fig. 6B). Infection with rAd:IB but not rAd:null also resulted in an extremely significant reduction in both MMP-1 upregulation by 97±4% (P<0.0001, n=5) and MMP-3 upregulation by 94±7% (P<0.0001, n=5), (Fig. 6A,B). These data clearly indicate that activation of NF-B is essential to upregulate MMPs-1, -3 and -9 in rabbit and human vascular smooth muscle cells.

View larger version (47K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 5 Adenovirus mediated expression of IB inhibits secretion of MMP-1, -3 and -9 in rabbit VSMC. Rabbit VSMC were infected with rAd:null or rAd:IB and rendered quiescent by serum deprivation for 72 h. (A) Cells were stimulated for 18 h with either 10 ng/ml IL-1, 20 ng/ml bFGF. 20 ng/ml PDGFBB or a combination of IL-1 with either PDGFBB or bFGF. While 10–7 M PMA (phorbol ester) was used as a positive control. Cell conditioned medium was collected and analysed for MMP-2 and MMP-9 secretion by gelatin zymography. (B) Quiescent VSMC infected with rAd:null or rAd:IB (as above) were stimulated with IL-1 plus bFGF for 18 h. Cell conditioned medium was collected and analysed for MMP-1 and -3 secretion by Western blotting. The results are representative of three separate experiments.

 

View larger version (46K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 6 Adenovirus mediated expression of IB inhibits secretion of MMP-1, -3 and -9 in human VSMC. Human VSMC were infected with rAd:null or rAd:IB and rendered quiescent by serum deprivation for 72 h. Cells were then incubated in serum free media or serum free media supplemented with 10 ng/ml IL-1 plus 20 ng/ml PDGFBB for 48 h. Cell conditioned media was collected and concentrated 10-fold before being analysed for (B) MMP-9 secretion by gelatin zymography and MMP-1 and -3 secretion by western blotting. (A) Gelatin zymograms and Western blots were analysed by densitometry using Molecular Analyst software. Values are mean±S.E.M. of three separate experiments.

 

	4 Discussion

Top Abstract 1 Introduction 2 Experimental procedures 3 Results 4 Discussion References

 
We confirmed our previous data showing synergistic regulation of MMP-9 by PDGF and IL-1 in rabbit smooth muscle cells [9] and extended this to human smooth muscle cells. We showed furthermore that additive or synergistic interactions between growth factors and cytokines apply also to MMP-1, and -3 secretion by VSMC from both species. The effects on MMP secretion in rabbit VSMC were accompanied by parallel changes in steady-state mRNA levels.

Upregulation of MMP secretion by IL-1 implies an association between increased matrix turnover and inflammation. Indeed, Lee and co-workers [26,27] demonstrated that macrophages stimulate VSMC to produce MMP-1 and -3 via secretion of IL-1β. Increased secretion of MMPs in response to IL-1 in the presence of growth factors further implies an association with inflammation and cell injury, which can be sources of PDGF and bFGF [2]. For example, in atherosclerosis, expression of PDGF, IL-1 and TNF- is known to occur together [2], and this may help to explain the presence of MMP-1, -3 and -9 in lesions [28–30]. The preponderant location of MMP-9, MMP-1 and MMP-3 at the shoulder regions of plaques, where there are abundant inflammatory cells is also consistent with an influence of locally released growth factors and inflammatory cytokines [28,31,32]. The consequences of excessive matrix remodelling in vascular pathology may be plaque rupture leading to myocardial infarction [33,34] or disruption of the vascular media leading to aneurysm formation [35,36].

In response to vascular injury, release of bFGF from intracellular compartments is believed to be an important immediate event [37], with PDGF production a more sustained consequence [38,39]. Induction of MMP-9 occurs early after injury to the rat [40,41] and pig [42] carotid artery and is sustained for several days, so that both bFGF and PDGF may play an important part in this response. Our data imply that there is a simultaneous requirement for an inflammatory cytokine, perhaps IL-1 or TNF. The similar pattern of regulation of MMP-1, -3 and -9 protein secretion implies that concerted turnover of all extracellular matrix components may occur after injury and inflammation. This may be important, in part, as a regulatory cascade, since MMP-3 can activate both MMP-1 and -9 [43,44].

Much further work, which is beyond the scope of the present study, is necessary to elucidate the mechanisms underlying the synergistic regulation of MMP secretion by growth factors and cytokines. We focused instead on defining the role played by the NF-B transcription factor in the upregulation of MMPs in VSMC. A functional NF-B site occurs in the proximal stimulatory region of the MMP-9 promoter [45,46] and deletion of this site reduces upregulation of reporter gene constructs in response to phorbol ester and TNF-. Until now, however it has been unclear what contribution NF-B plays in the upregulation of the endogenous MMP-9 gene. For example, transient overexpression IB in mesangial cells only partially impaired upregulation of MMP-9, suggesting that NF-B simply plays a permissive role in the upregulation of MMP-9 [47]. Our present results demonstrate, however, an absolute requirement for NF-B activity, in addition to the essential role played by the AP-1 transcription factor, for MMP-9 production in rabbit and human VSMC in response to a wide variety of stimuli including cytokines, growth factors and phorbol esters [45,46]. Our parallel studies in rabbit dermal fibroblasts also demonstrated an absolute requirement for NF-B in MMP-9 secretion in this cell type [19].

Our present results further demonstrate that NF-B activity is essential for upregulation of MMP-1 and -3 in rabbit and human vascular smooth muscle cells. In the case of MMP-1, this is consistent with the observations by Vincenti et al. [15], who used reporter gene analysis of the MMP-1 promoter sequence. An NF-B-like element was identified at nucleotides –3030 to –3000 that was required, in addition to the proximal AP-1 binding site at –70, for IL-1β stimulated MMP-1 promoter activity in synovial fibroblasts [50]. Furthermore, Xu et al. [48] demonstrated that a peptide inhibitor targeted at nuclear translocation of NF-B inhibited MMP-1 expression by human fibroblasts grown in a three-dimensional collagen lattice. The importance of NF-B for increased secretion of MMP-3 is more surprising because no consensus NF-B element has yet been identified in its promoter [49]. However, it is possible that NF-B regulates this gene via an, as yet unidentified NF-B element or via interactions with other transcription factors that regulate MMP-3 expression. For example, Stein et al. [51] demonstrated that NF-B can potentiate transcription from promoters lacking NF-B elements via interactions with AP-1 transcription factor. Furthermore, a requirement for NF-B in the upregulation of 2 integrin expression in fibroblasts also occurs in the absence of known NF-B promoter elements. Future studies will address the presumably indirect mechanism underlying the regulation of MMP-3 secretion by NF-B, which also occurs in rabbit dermal fibroblasts [52].

Our demonstration that NF-B activity is essential for MMP-1, -3 and -9 secretion probably explains previous data showing that the anti-oxidant, N-acetyl-cysteine, inhibits MMP production [53]. N-acetyl-cysteine is a known inhibitor of NF-B activity. Furthermore, inhibition of NF-B activity may play a role in the inhibition of MMP secretion by HMG-CoA reductase inhibitors [54,55]. Our data also provides further impetus to pursue the use of specific pharmacological inhibitors of NF-B activation or decoy NF-B oligonucleotides [56], and evaluate them in the context of unstable angina pectoris and myocardial infarction.

Time for primary review 23 days.

	Acknowledgements

 
This work was supported by the Biotechnology and Biological Science Research Council (BBSRC) and the British Heart Foundation (BHF).

	References

Top Abstract 1 Introduction 2 Experimental procedures 3 Results 4 Discussion References

 

1. Ross R. Atherosclerosis: A defence mechanism gone awry. Am J Pathol (1993) 143:987–1002.[Web of Science][Medline]
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 362:801–808.[CrossRef][Medline]
3. Galis Z.S., Sukhova G.K., Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. (1995) 9:974–980.[Abstract]
4. Galis Z., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinase and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 94:2493–2503.[Web of Science][Medline]
5. Galis Z., Sukhova G., Libby P. Evidence for presence of activated matrix metalloproteinases in human atherosclerotic plaques. FASEB J (1994) 8:A661–A663.
6. Galis Z.S., Muszynski M., Sukhova G.K., Simonmorrissey E., Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci (1995) 748:501–507.[Web of Science][Medline]
7. Galis Z.S., Sukhova G.K., Libby P. Microscopic localisation of active proteases by in situ zymography: Detection of matrix metalloproteinase activity in vascular tissue. FASEB J. (1995) 9:974–980.[Abstract]
8. Galis Z.S., Muszynski M., Sukhova G.K., et al. Cytokine-stimulated human vascular smooth-muscle cells synthesize a complement of enzymes required for extracellular-matrix digestion. Circ Res (1994) 75:181–189.[Abstract/Free Full Text]
9. Fabunmi R.P., Baker A.H., Murray E.J., Booth R.F., Newby A.C. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem. J. (1996) 315:335–342.[Web of Science][Medline]
10. Baeuerle P.A., Henkel T. Function and activation of NF-kB in the immune system. Annu. Rev. Immunol. (1994) 12:141–179.[Web of Science][Medline]
11. Baeuerle P.A., Baltimore P.A. NF-B: Ten years after. Cell (1996) 87:13–20.[CrossRef][Web of Science][Medline]
12. Brand K., Page S., Rogler G., et al. Activated transcription factor nuclear factor-kappa-B is present in the atherosclerotic lesion. J. Clin. Invest. (1996) 97:1715–1722.[Web of Science][Medline]
13. Sato H., Seiki M. Regulatory mechanism of 92 kD type IV collagenase gene expression which is associated with invasiveness of tumour cells. Oncogene (1993) 8:395–405.[Web of Science][Medline]
14. Fini M.E., Bartlett J.D., Matsubara M., et al. The rabbit gene for 92-kDa Matrix metalloproteinase. J. Biol. Chem. (1994) 269:28620–28628.[Abstract/Free Full Text]
15. Vincenti M.P., Coon C.I., Brinckerhoff C.E. Nuclear factor kappa B p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1 beta-stimulated synovial fibroblasts. Arthritis Rheum (1998) 41:1987–1994.[CrossRef][Web of Science][Medline]
16. Wrighton C.J., Hofer-Warbinek R., Eytner R., Moll T., Bach F.H., de Martin R. Inhibition of endothelial cell activation by adenovirus mediated expression of IkB-alpha, an inhibitor of the transcription factor NF-B. J. Exp. Med. (1996) 483:1013–1022.
17. Wilkinson G.W.G., Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res (1992) 20:2233–2239.[Abstract/Free Full Text]
18. Southgate K.M., Davies M., Booth R.F., Newby A.C. Involvement of extracellular-matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem. J. (1992) 288:93–99.[Web of Science][Medline]
19. Bond M., Fabunmi R.P., Baker A.H., Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kB. FEBS Lett (1998) 435:29–34.[CrossRef][Web of Science][Medline]
20. Fabunmi R.P., Baker A.H., Murray E.J., Booth R.F.G., Newby A.C. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem. J. (1996) 315:335–342.[Web of Science][Medline]
21. Onisto M., Garbisa S., Caenazzo C., et al. Reverse transcription-polymerase chain reaction phenotyping of metalloproteinases and inhibitors involved in tumour matrix invasion. Diagn. Mol. Pathol. (1993) 2:74–80.[Web of Science][Medline]
22. Sanz L., Berra E., Munico M.M., Dominguez I. Zeta PKC plays a critical role during stromelysin promoter activation by PDGF through a novel palindromic element. J. Biol. Chem. (1994) 269:10044–10049.[Abstract/Free Full Text]
23. Channon K.M., Blasing M.A., Shetty G.A., Potts K.E., George S.E. Adenoviral gene transfer of nitric oxide synthase: high level of expression in human vascular cells. Cardiovasc Res (1996) 32:962–972.[Abstract/Free Full Text]
24. Barnes P.J., Karin M. Nuclear factor kappa-B: A pivotal transcription factor in chronic inflammatory diseases. New Engl J Med (1996) 336:1066–1071.[Web of Science]
25. Borgland S.L., Bowen G.P., Wong N.C.W., Libermann T.A., Muruve D.A. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappa B. J Virol (1996) 74:3941–3947.[CrossRef]
26. Lee E., Grodzinsky A.J., Libby P., Clinton S.K., Lark M.W., Lee R.T. Human vascular smooth-muscle cell–monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol (1995) 15:2284–2289.[Abstract/Free Full Text]
27. Lee E., Grodzinsky A.J., Libby P., Clinton S.K., Lark M.W., Lee R.T. Monocytes induce metalloproteinase secretion by cultured human vascular smooth-muscle cells through interleukin-1. Circulation (1995) 92:2025–2028.[Web of Science]
28. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. (1994) 94:2493–2503.[Web of Science][Medline]
29. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively express matrix-degrading proteases. Proc Natl Acad Sci USA (1995) 92:402–406.[Abstract/Free Full Text]
30. Zaltsman A.B., Newby A.C. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis (1997) 130:61–70.[CrossRef][Web of Science][Medline]
31. Lee R.T., Schoen F.J., Loree H.M., Lark M., Libby P. Circumferential stress and matrix metalloproteinase 1 in human atherosclerosis. Implication for plaque rupture. Arterioscler Thromb Vasc Biol (1996) 16:1070–1073.[Abstract/Free Full Text]
32. Nikkari S.T., O'Brien K.D., Ferguson M.H., Welgus H.G., Alpers C.E., Clowes A.W. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation (1995) 92:1393–1398.[Abstract/Free Full Text]
33. Libby P. Molecular basis of the acute coronary syndromes. Circulation (1995) 91:2844–2850.[Free Full Text]
34. Henney A.M., Wakeley P.R., Davies M.J., et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. USA (1991) 88:8154–8158.[Abstract/Free Full Text]
35. Herron S., Unemori E., Wong M., Rapp J., Hibbs M., Stoney R. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms. Involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. Atherioscler Thromb (1991) 11:1667–1677.
36. McMillian W., Patterson B., Keen R., Shively V., Cipollone M., Pearce W. In situ localisation and quantification of mRNA for 92 kD type-IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol (1995) 15:1139–1144.[Abstract/Free Full Text]
37. Lindner V., Lappi D.A., Baird A., Majack R., Reidy M.A. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res (1991) 68:106–113.[Abstract/Free Full Text]
38. Jackson C., Raines E., Ross R., Reidy M. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb (1993) 13:1218–1226.[Abstract/Free Full Text]
39. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplast by an antibody to PDGF. Science (1991) 25:1129–1133.
40. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. (1994) 75:539–545.[Abstract/Free Full Text]
41. Zempo N., Kenagy R.D., Au T.Y.P., et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J. Vasc Surg (1994) 20:209–217.[Web of Science][Medline]
42. Southgate K.M., Fisher M., Banning A.P., et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. (1996) 79:1177–1187.[Abstract/Free Full Text]
43. Murphy G., Cockett M.I., Stephens P.E., Smith B.J., Docherty A.J.P. Stromelysin is an activator of pro-collagenase. Biochem. J. (1987) 248:265–268.[Web of Science][Medline]
44. Shapiro S.D., Fliszar C.J., Brockelman T.J., Mecham R.P., Stenior R.M., Welgus H.G. Activation of the 92 kD gelatinase by stromelysin and 4-aminophenylmercuric acetate. J. Biol. Chem. (1995) 270:6351–6356.[Abstract/Free Full Text]
45. Sato H., Seiki M. Regulatory mechanism of 92-kDa Type-IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene (1993) 8:395–405.[Web of Science][Medline]
46. Fini M.E., Bartlett J.D., Matsubara M., et al. The rabbit gene for 92-kDa matrix metalloproteinase: Role of AP1 and AP2 in cell type-specific transcription. J Biol Chem. (1994) 269:28620–28628.[Abstract/Free Full Text]
47. Yokoo T., Kitamura M. Dual regulation of IL-1B-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kB and AP-1. Am. J. Physiol. (1996) 270:F123–F130.[Web of Science][Medline]
48. Xu J.H., Zutter M.M., Santoro S.A., Clark R.A.F. A three-dimensional collagen lattice activates NF-kappa B in human fibroblasts: Role in integrin alpha(2) gene expression and tissue remodeling. J Cell Biol (1998) 140:709–719.[Abstract/Free Full Text]
49. Frisch S.M., Ruley H.E. Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone. J. Biol. Chem. (1987) 262:16300–16304.[Abstract/Free Full Text]
50. Vincenti M.P., Coon C.I., Lee O., Brinckerhoff C.E. Regulation of collagenase gene expression by IL-1B requires transcriptional and post-transcriptional mechanisms. Nucleic Acids Res (1994) 22:4818–4827.[Abstract/Free Full Text]
51. Stein B., Baldwin A.S., Ballard D.W., Green W.C., Angle P., Herrlich P. Cross-coupling of the NF-kB p65 and Fos/Jun transcription factors produced potentiated biological function. EMBO J (1996) 12:3879–3891.
52. Bond M., Baker A.H., Newby A.C. Nuclear factor B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun (1999) 264:561–567.[CrossRef][Web of Science][Medline]
53. Galis Z.S., Asanuma K., Godin D., Meng X.P. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: New target for antioxidant therapy? Circulation (1998) 97:2445–2453.[Abstract/Free Full Text]
54. Bellosta S., Ferri N., Arnaboldi L., Bernini F., Paoletti R., Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care (2000) 23:B72–U75.[Web of Science][Medline]
55. Marz W., Wieland H. HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? Herz (2000) 25:117–125.[CrossRef][Web of Science][Medline]
56. Suzuki J., Morishita R., Kaneda Y., Isobe M. Decoy against nuclear factor kappa-B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther (1996) 7:1847–1852.[CrossRef]

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				J. Nischan, Z. Gatalica, M. Curtis, G. M. Lenk, G. Tromp, and H. Kuivaniemi Binding Sites for ETS Family of Transcription Factors Dominate the Promoter Regions of Differentially Expressed Genes in Abdominal Aortic Aneurysms Circ Cardiovasc Genet, December 1, 2009; 2(6): 565 - 572. [Abstract] [Full Text] [PDF]

				A. W. Orr, M. Y. Lee, J. A. Lemmon, A. Yurdagul Jr, M. F. Gomez, P. D. Schoppee Bortz, and B. R. Wamhoff Molecular Mechanisms of Collagen Isotype-Specific Modulation of Smooth Muscle Cell Phenotype Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 225 - 231. [Abstract] [Full Text] [PDF]

				A. C. Newby Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2108 - 2114. [Abstract] [Full Text] [PDF]

				Y. Kondo, K. Fukuda, T. Adachi, and T. Nishida Inhibition by a Selective I{kappa}B Kinase-2 Inhibitor of Interleukin-1-Induced Collagen Degradation by Corneal Fibroblasts in Three-Dimensional Culture Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4850 - 4857. [Abstract] [Full Text] [PDF]

				S. Delbosc, M. Glorian, A.-S. Le Port, G. Bereziat, M. Andreani, and I. Limon The Benefit of Docosahexanoic Acid on the Migration of Vascular Smooth Muscle Cells Is Partially Dependent on Notch Regulation of MMP-2/-9 Am. J. Pathol., May 1, 2008; 172(5): 1430 - 1440. [Abstract] [Full Text] [PDF]

				S. Lehoux Redox signalling in vascular responses to shear and stretch Cardiovasc Res, July 15, 2006; 71(2): 269 - 279. [Abstract] [Full Text] [PDF]

				K. Fukuda, Y. Fujitsu, N. Kumagai, and T. Nishida Inhibition of matrix metalloproteinase-3 synthesis in human conjunctival fibroblasts by interleukin-4 or interleukin-13. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2857 - 2864. [Abstract] [Full Text] [PDF]

				C Boileau, J Martel-Pelletier, J Brunet, D Schrier, C Flory, M Boily, and J-P Pelletier PD-0200347, an {alpha}2{delta} ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKC{alpha} dependent effect Ann Rheum Dis, May 1, 2006; 65(5): 573 - 580. [Abstract] [Full Text] [PDF]

				M. Cohen, A. Meisser, L. Haenggeli, and P. Bischof Involvement of MAPK pathway in TNF-{alpha}-induced MMP-9 expression in human trophoblastic cells Mol. Hum. Reprod., April 1, 2006; 12(4): 225 - 232. [Abstract] [Full Text] [PDF]

				A. C. Newby Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates Cardiovasc Res, February 15, 2006; 69(3): 614 - 624. [Abstract] [Full Text] [PDF]

				S. Rutschow, J. Li, H.-P. Schultheiss, and M. Pauschinger Myocardial proteases and matrix remodeling in inflammatory heart disease Cardiovasc Res, February 15, 2006; 69(3): 646 - 656. [Abstract] [Full Text] [PDF]

				K. Trescher, O. Bernecker, B. Fellner, M. Gyongyosi, R. Schafer, S. Aharinejad, R. DeMartin, E. Wolner, and B. K. Podesser Inflammation and postinfarct remodeling: Overexpression of I{kappa}B prevents ventricular dilation via increasing TIMP levels Cardiovasc Res, February 15, 2006; 69(3): 746 - 754. [Abstract] [Full Text] [PDF]

				T. S. Perlstein and R. T. Lee Smoking, Metalloproteinases, and Vascular Disease Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 250 - 256. [Abstract] [Full Text] [PDF]

				A. Moran, P. Iniesta, C. de Juan, C. Garcia-Aranda, A. Diaz-Lopez, and M. Benito Impairment of Stromelysin-1 Transcriptional Activity by Promoter Mutations in High Microsatellite Instability Colorectal Tumors Cancer Res., May 1, 2005; 65(9): 3811 - 3814. [Abstract] [Full Text] [PDF]

				A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]

				P. Zahradka, G. Harding, B. Litchie, S. Thomas, J. P. Werner, D. P. Wilson, and N. Yurkova Activation of MMP-2 in response to vascular injury is mediated by phosphatidylinositol 3-kinase-dependent expression of MT1-MMP Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2861 - H2870. [Abstract] [Full Text] [PDF]

				S. Meiners, B. Hocher, A. Weller, M. Laule, V. Stangl, C. Guenther, M. Godes, A. Mrozikiewicz, G. Baumann, and K. Stangl Downregulation of Matrix Metalloproteinases and Collagens and Suppression of Cardiac Fibrosis by Inhibition of the Proteasome Hypertension, October 1, 2004; 44(4): 471 - 477. [Abstract] [Full Text] [PDF]

				S.-K. Moon, H.-M. Kim, Y.-C. Lee, and C.-H. Kim Disialoganglioside (GD3) Synthase Gene Expression Suppresses Vascular Smooth Muscle Cell Responses via the Inhibition of ERK1/2 Phosphorylation, Cell Cycle Progression, and Matrix Metalloproteinase-9 Expression J. Biol. Chem., August 6, 2004; 279(32): 33063 - 33070. [Abstract] [Full Text] [PDF]

				C. Monaco, E. Andreakos, S. Kiriakidis, C. Mauri, C. Bicknell, B. Foxwell, N. Cheshire, E. Paleolog, and M. Feldmann Canonical pathway of nuclear factor {kappa}B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis PNAS, April 13, 2004; 101(15): 5634 - 5639. [Abstract] [Full Text] [PDF]

				E. W. Raines, K. J. Garton, and N. Ferri Beyond the Endothelium: NF-{kappa}B Regulation of Smooth Muscle Function Circ. Res., April 2, 2004; 94(6): 706 - 708. [Full Text] [PDF]

				Y. Nakano, S. Niida, K. Dote, S. Takenaka, H. Hirao, F. Miura, M. Ishida, T. Shingu, T. Sueda, M. Yoshizumi, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation J. Am. Coll. Cardiol., March 3, 2004; 43(5): 818 - 825. [Abstract] [Full Text] [PDF]

				C. Monaco and E. Paleolog Nuclear factor {kappa}B: a potential therapeutic target in atherosclerosis and thrombosis Cardiovasc Res, March 1, 2004; 61(4): 671 - 682. [Abstract] [Full Text] [PDF]

				H. M. Wang, X. Zhang, D. Qian, H. Y. Lin, Q. L. Li, D. L. Liu, G. Y. Liu, X. D. Yu, and C. Zhu Effect of Ubiquitin-Proteasome Pathway on Mouse Blastocyst Implantation and Expression of Matrix Metalloproteinases-2 and -9 Biol Reprod, February 1, 2004; 70(2): 481 - 487. [Abstract] [Full Text] [PDF]

				Z. Strakova, M. Szmidt, S. Srisuparp, and A. T. Fazleabas Inhibition of Matrix Metalloproteinases Prevents the Synthesis of Insulin-Like Growth Factor Binding Protein-1 during Decidualization in the Baboon Endocrinology, December 1, 2003; 144(12): 5339 - 5346. [Abstract] [Full Text] [PDF]

				T.-l. Yue, W. Bao, B. M. Jucker, J.-l. Gu, A. M. Romanic, P. J. Brown, J. Cui, D. T. Thudium, R. Boyce, C. L. Burns-Kurtis, et al. Activation of Peroxisome Proliferator-Activated Receptor-{alpha} Protects the Heart From Ischemia/Reperfusion Injury Circulation, November 11, 2003; 108(19): 2393 - 2399. [Abstract] [Full Text] [PDF]

				D. Q. Li, T. Y. Shang, H.-S. Kim, A. Solomon, B. L. Lokeshwar, and S. C. Pflugfelder Regulated Expression of Collagenases MMP-1, -8, and -13 and Stromelysins MMP-3, -10, and -11 by Human Corneal Epithelial Cells Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2928 - 2936. [Abstract] [Full Text] [PDF]

				P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1927 - 1939. [Full Text] [PDF]

				N. Ferri, K. J. Garton, and E. W. Raines An NF-{kappa}B-dependent Transcriptional Program Is Required for Collagen Remodeling by Human Smooth Muscle Cells J. Biol. Chem., May 23, 2003; 278(22): 19757 - 19764. [Abstract] [Full Text] [PDF]

				Z. Luan, A. J. Chase, and A. C. Newby Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 769 - 775. [Abstract] [Full Text] [PDF]

				J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF]

				Y. Bayon, M. A. Ortiz, F. J. Lopez-Hernandez, F. Gao, M. Karin, M. Pfahl, and F. J. Piedrafita Inhibition of I{kappa}B Kinase by a New Class of Retinoid-Related Anticancer Agents That Induce Apoptosis Mol. Cell. Biol., February 1, 2003; 23(3): 1061 - 1074. [Abstract] [Full Text] [PDF]

				S. Hussain, J. W. Assender, M. Bond, L.-F. Wong, D. Murphy, and A. C. Newby Activation of Protein Kinase Czeta Is Essential for Cytokine-induced Metalloproteinase-1, -3, and -9 Secretion from Rabbit Smooth Muscle Cells and Inhibits Proliferation J. Biol. Chem., July 19, 2002; 277(30): 27345 - 27352. [Abstract] [Full Text] [PDF]

				A. J. Chase, M. Bond, M. F. Crook, and A. C. Newby Role of Nuclear Factor-{kappa}B Activation in Metalloproteinase-1, -3, and -9 Secretion by Human Macrophages In Vitro and Rabbit Foam Cells Produced In Vivo Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 765 - 771. [Abstract] [Full Text] [PDF]

				Y. Jiang and R. J. Muschel Regulation of Matrix Metalloproteinase-9 (MMP-9) by Translational Efficiency in Murine Prostate Carcinoma Cells Cancer Res., March 1, 2002; 62(6): 1910 - 1914. [Abstract] [Full Text] [PDF]

				W. S. Bradham, B. Bozkurt, H. Gunasinghe, D. Mann, and F. G. Spinale Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective Cardiovasc Res, March 1, 2002; 53(4): 822 - 830. [Abstract] [Full Text] [PDF]

This Article Abstract FREE Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Disclaimer Google Scholar Articles by Bond, M. Articles by Newby, A. C Search for Related Content PubMed PubMed Citation Articles by Bond, M. Articles by Newby, A. C Social Bookmarking          What's this?

Online ISSN 1755-3245 - Print ISSN 0008-6363

Copyright © 2010 European Society of Cardiology

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics